Navigation Links
Invest in Cures Forum November 1 Offers Insights, Connections into Impact Investing in Healthcare
Date:10/11/2018

LaunchBio, Inc., a nonprofit organization that identifies, counsels, and supports high-growth, high-impact life science and biotechnology companies, announced today that it will host a forum with investment professionals representing 8 national nonprofit disease foundations to discuss their investment philosophies, explain their fund and deal structures, and describe how they are using deep scientific knowledge to validate early stage technologies and syndicate with other investors.

The program, called Invest in Cures, is scheduled for November 1 from 4-7 p.m. at the North Carolina Biotechnology Center, one of the presenting partners for the forum. North Carolina Biosciences Organization (NCBIO), BioLabs North Carolina, and the Council for Entrepreneurial Development (CED) also are joining LaunchBio as presenting partners for this event.

Nonprofit foundations increasingly are making investments in life science companies to accelerate the pace of commercialization of technologies that may provide new therapies and cures for patients. No longer solely focused on making grants to researchers, disease foundations are creating a range of investment vehicles to achieve their missions.

“We are interested in new sources of capital for early stage life science companies, and see non-traditional investors, such as these foundations, as an important addition to the network,” says Joan Siefert Rose, CEO of LaunchBio. “As disease foundations start venture arms and add investment professionals to their teams, the organizations hosting this forum want to make sure they are meeting other investors and learning about promising companies in North Carolina. Our expectation is that they will find good opportunities here, and return frequently,” she says.

The confirmed speakers for the forum are:

Mark Allegretta, PhD
VP, Commercial Research
National Multiple Sclerosis Society

Jonathan Behr, PhD
Managing Director
T1D Fund, Juvenile Diabetes Research Foundation

Bob Crutchfield
Managing Director
BrightEdge Ventures Fund, American Cancer Society

Gerard Honig, PhD
Manager, Translational Research
IBD Ventures, Crohn’s and Colitis Foundation

Debra Miller
President & CEO
CureDuchenne Ventures

Chris Penland, PhD
Vice President, Biopharma Programs
Cystic Fibrosis Foundation

Barbara Tate, PhD
Venture Partner
Dementia Discovery Fund

Ben Yerxa, PhD
CEO
Retinal Degeneration Fund, Foundation Fighting Blindness

The Invest in Cures forum is part of LaunchBio’s monthly gathering for the biotech community, Larger Than Life Science. Information and registration are available at https://www.launchbio.org/event/invest-in-cures.

About LaunchBio: LaunchBio is a nonprofit organization that identifies, counsels, and supports high-growth, high-impact life science and biotechnology companies. Its mission is to build an ecosystem of innovation for the benefit of human health and well-being.

LaunchBio’s impact is measured by its success in connecting entrepreneurs with knowledge, capital and talent – including each other – not only within geographic regions, but across the nation’s leading life science hubs. LaunchBio offers programs in Durham, NC; San Diego, CA; Boston, MA; and soon will expand to New York City.

Read the full story at https://www.prweb.com/releases/invest_in_cures_forum_november_1_offers_insights_connections_into_impact_investing_in_healthcare/prweb15822470.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. CallTower Continues to Invest in Skype?for Business?for?Companies with Less than?500 Users
2. Clinical Trial Investigates Multicolor Tattoo Removal in Fewer Treatments
3. Plum Alley Closes $1.5M in Syndicate with Women and Men Investing in CRISPR-based Diagnostics Company
4. Global Biometric Vehicle Access System Market 2013-2016 & 2025: $1.58 Billion Growth Opportunities/Investment Opportunities - Research and Markets
5. Strategic Cyber Ventures Leads $3.5M Investment in Polarity
6. Global Military Biometrics Market Growth at 7.5%, 2016-2020 - Technologies Being Used for Local, State & Federal Investigations - Research and Markets
7. Venture Fund with Key Focus on Alzheimers Announces Investment in M3 Biotechnology and Its Drug Aimed at Regrowing Brain Cells
8. License plate reader and historical license plate reader data used in homicide investigation
9. Synaptics to Present at Upcoming Investor Conferences
10. Polygraph Test Now Used to Protect Investors From Fraud
11. Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2018)... ... October 03, 2018 , ... Orbsen ... first-in-class stromal cell immunotherapies, announced that ORBCEL-M™, a second generation stromal cell ... progressive diabetic kidney disease in a four-site, pan-European Phase I/II clinical trial. ...
(Date:10/2/2018)... ... 2018 , ... Stuart is a fun-loving eight-year-old Labrador retriever. Like many labs, Stuart’s favorite ... loves playing ball so much that whenever anyone comes to our door, he grabs a ... fetch.” In early 2017, Stuart began limping and eventually could no longer play fetch. ...
(Date:10/2/2018)... ... October 02, 2018 , ... The ... 27th, 2018 at Tampa Convention Center. The Palo Alto-based face recognition company, Camvi ... on September 27th. Other speakers included U.S. Federal executives from Department of Defense ...
Breaking Biology News(10 mins):
(Date:9/27/2018)... EWING, N.J. (PRWEB) , ... September 26, 2018 ... ... and DNA testing are way ahead of their primary care physicians, according to ... , For this study, patients and doctors were asked about consumer adoption of ...
(Date:9/27/2018)... ... September 27, 2018 , ... This past weekend ... SureAdhere Mobile Technology, Inc. announced they will formally merge companies and integrate their ... tuberculosis (TB) and other diseases. These two social enterprise corporations, both of which ...
(Date:9/22/2018)... (PRWEB) , ... September 20, ... ... are excited to announce a strategic venture. The synergistic combination of Predicine’s ... provides complimentary and comprehensive biomarker profiling to empower clinical trials in the ...
(Date:9/15/2018)... ... September 14, 2018 , ... Next-generation genomic sequencing is transforming ... new technologies, challenges remain. In the past, the sheer size of genomics data has ... is a new data ecosystem developed to advance cures by reducing the technological barriers ...
Breaking Biology Technology: